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The diagnostic and therapeutic approach to prostatic neurosarcoma, currently known as a malignant peripheral nerve 
sheath tumor (MPNst) of the prostate, due to its rarity, is not well established. Our presenting case was a 73 year old 
patient, admitted to the Hospital with suspicion of a prostatic tumor. The patient underwent surgical resection of 
the described pathological mass. Gross appearance of the pathological examination revealed a yellow-gray colored 
tumor, 12 × 6 × 7 cm in size. On cross-section: tumor heterogeneity, fatty, yellow-gray, with no foci of necrosis, but 
with a few cysts of 1–3 cm in size, with a gelatinous substance. Microscopic examination — showed neurosarcoma 
of the prostate. The patient died at six months follow-up, due to cardiovascular insufficiency.
Złośliwy nowotwór osłonek nerwów obwodowych o umiejscowieniu w sterczu
Postępowanie diagnostyczne i terapeutyczne u pacjentów z nerwiakomięsakami prostaty (aktualnie klasyfikowanymi 
jako złośliwe nowotwory osłonek nerwów obwodowych) pozostaje nieokreślone z powodu rzadkiej na nie zapadalno-
ści. Przedstawiamy przypadek 73-letniego chorego, przyjętego do szpitala z powodu nowotworu stercza, który został 
poddany wycięciu zmiany. Makroskopowo stwierdzono żółto-szarawy guz o wymiarach 12 × 6 × 7 cm, na przekroju 
o niejednorodnej budowie z zawartością tkanki tłuszczowej, bez ognisk martwicy, ale z obecnością kilku torbieli 
o wymiarach 1–3 cm, wypełnionych treścią galaretowatą. Badanie mikroskopowe ujawniło cechy nerwiakomięsaka. 
Pacjent zmarł sześć miesięcy po operacji w następstwie niewydolności krążenia.
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Introduction
Malignant peripheral nerve tumors, which include neu-
rosarcoma derived from Schwann-Cells, are described in the 
literature under different names: schwannoma malignum, 
neurilemmoma malignum or sarcoma neurogenes. Cur-
rently, this cancer is usually described in the anglo-saxon 
literature as a malignant peripheral nerve sheath tumor 
(HPNSts), occurring on the limbs or neck. Other locations, 
including retroperitoneal, associated with a bunch of cer-
ebrovascular nerve are rare. The aim of this paper is to briefly 
present a very unusual case of prostatic localization of the 
tumor.
Case report
A 73 year old patient, was admitted to the Hospital with 
suspicion of a prostatic tumor. The patient reported pain 
around the sacrum and disturbances in passing stool, urine 
flow impairment, nocturia 1× for about one year in duration. 
There was no urinary retention or hematuria. The level of PSA 
was 1.15 ng/ml. Performed biopsy of the prostate revealed 
normal prostate tissue. Intravenous urography (figure 1) 
showed an irregular mass modelling the right upper wall 
of the bladder. An ultrasound scan showed a solid structure 
measuring about 100 mm at the right-hand-side posterior 
bladder wall (cross section figure 2).
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The patient underwent surgical resection of the de-
scribed pathological mass. A tumor of about 120 mm in 
diameter was found between the rectum and bladder wall 
with a clear lateralization of the right side. The cecum was 
manually moved away upwards, the peritoneum was incised 
over the tumor and a fairly easy cleavage plan appeared. The 
tumor was enucleated without any major problems. How-
ever major bleeding from perirectal and peribladder veins 
occurred. During management to stop the bleeding, the 
right ureter was knowingly “en masse” punctured to facilitate 
Figure 1. Urography. Displacement of the bladder to the left, and 
modelling of the upper-right side of its wall. Upward displacement 
and bending of the lower part of the right ureter
Figure 2. US-scan. Transverse section of the small pelvis. The solid tumor about 100 mm long at the posterior wall of the right-side of the bladder
Figure 3. Elastic, yellow-gray tumor 12 × 6 × 7 in diameter
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hemostasis. In the next step, the bladder was opened. The 
ureter was cut over the puncture and was transplanted to 
the bottom of the bladder. The postoperative course was 
complicated by the left epididymitis, which was managed 
by gentamycin administration. The patient was discharged 
with a mild urinary incontinence. The patient died at six 
months follow-up, probably due to cardiovascular insuf-
ficiency.
Gross appearance of the pathological examination re-
vealed a yellow-gray colored tumor, 12 × 6 × 7 cm in size 
(figure 3). On cross-section: tumor heterogeneity, fatty, 
yellow-gray, with no foci of necrosis, but with a few cysts 
of 1–3 cm in size, with the gelatinous substance in the larg-
est one, clearly to stratify, quite thick bag with numerous 
vessels (figure 4). Tissue material (clippings) was developed 
routinely, using staining with hematoxylin and eosin and 
silver plating according to the Gomori formula and immu-
nohistochemical study of S-100 (a protein specific to the 
nervous system) (figures 5, 6, 7). Microscopic examination 
— showed Neurosarcoma of the prostate.
Discussion
Neurosarcomas, are described in the literature under 
different names: schwannoma malignum, neurilemmoma 
malignum or sarcoma neurogenes. According to Andrew L. 
Folpe and Carrie Y. Inwolds (Bone and soft tissue pathology 
2010, Elsevier Inc.) soft tissue sarcomas have been linked 
within families, so it is hypothesized that neurofibrosar-
coma may be genetic, although researchers still do not 
know the exact cause of the disease. Evidence supporting 
this hypothesis includes loss of heterozygosity on the 17p 
chromosome. The p53 (a tumor suppressor gene in the 
normal population) genome on 17p in neurofibrosarcoma 
patients is mutated, increasing the probability of cancer. The 
normal p53 gene will regulate cell growth and inhibit any 
uncontrollable cell growth in the healthy population; since 
Figure 4. On the cross-section: heterogenic tumor, fatty, yellow-gray, 
with no foci of necrosis, with few cysts 1–3 cm in size, the gelatinous 
substance in the largest one, clearly to stratify, quite thick bag with 
numerous vessels
Figure 5. Neurosarcoma weaving of delicate, elongated cells, with 
the presence of atypical cells. HE Staining
Figure 6. Hypercellular neurosarcoma texture. HE Staining
Figure 7. Immunohistochemical reaction for S-100
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p53 is inactivated in neurofibrosarcoma patients, they are 
much more susceptible to developing tumors.
Patients with NF1 experience development of MPNSTs 
at earlier ages. NF1-associated MPNST accounts for between 
50% and 67% of cases. A marked male predominance is seen 
with both sporadic and NF1-associated tumors. Currently, in 
the anglo-saxon literature this neoplasm is usually described 
as a malignant peripheral nerve sheath tumor (MPNSts). 
They belong to the group of malignant peripheral nerve 
sheath tumors (MPNST), highly malignant, infrequent soft 
tissue sarcomas of ectomesenchymal origin. The exact cell 
origin for these tumors has not been definitively confirmed 
yet, however it is known that neurosarcomas arise from 
major and minor peripheral branches or their sheaths [1]. 
Carcinogenesis in MPNSTs concerns mostly a suppressor 
NF1 gene aberration. Its product, neurofibromin, reduces 
proliferation of cells by inactivation of the protooncogene 
p21-ras [2]. Malignancies are locally invasive, may lead to re-
occurrence, as well as metastatic spread. The most common 
location is the sciatic nerve, followed by the brachial plexus; 
spinal nerve roots; the vagus, femoral, sacral plexus, pop-
liteal, obturator, posterior tibial, and ulnar nerves; and the 
vulva, posterior mediastinum, or retroperitoneal location [3].
Diagnosis of MPNST is usually based on one or more of 
following criteria:
1) association with peripheral nerve,
2) transformation of preexisting neurofibroma,
3) positive immunohistochemical reaction when using 
antibodies against peripheral nerve antigens [4].
Macroscopically they are fusiform, white masses, some-
times with hemorrhagic foci (especially in larger tumors). 
Microscopically the histologic differentiation is usually poor. 
The tumor is non-encapsulated, composed of spindle cells 
with comma-shaped nuclei, infiltrating the axis of the parent 
nerve and/or adjacent soft tissues. Degeneration effects are 
commonly observed, as necrosis or cyst formation. In 15% 
epithelioid components may also be seen [5].
For microscopic examination standard staining is used 
(hematoxylin-eosin and reticulin), as well as immunohisto-
chemical staining for final diagnostic confirmation. The ma-
ture Schwann cell marker S-100 is most prominent, however 
others are also used: desmin, myogenin, MIB-1 proliferation 
marker, Leu-7 myelin-associated glycoprotein, vimentin, 
myelin basic protein. Positive reaction with S-100 protein 
is observed in 50–90% of MPNST [6, 7]. 
Tumor size defines staging, while atypia and mitotic ac-
tivity defines grading of MPNST [8]. 5 centimeters is used as 
a border diameter of MPNST for prognostic purposes. Larger 
tumors are more often high grade, inoperable in terms of 
oncological radical surgery, and relatively frequently present 
with neurological deficits [4, 9–11]. For three-step grading 
(GI–GIII), the same criteria as for other tissue sarcomas, are 
used, thus cellularity, mitotic activity, cellular as well as 
nuclear atypia and anaplasia.
In general, patients with MPNSTs have a poor prog-
nosis. Five-year overall survival is reported to be as low as 
16–52% [12–14]. Even with aggressive surgical and adjuvant 
therapy, local recurrence is diagnosed in 50% of cases [15]. 
The main reason for death is hematogenous spread to the 
lungs, less commonly to the liver, brain, soft tissue, bones, 
regional lymph nodes, skin or retroperitoneum [14].
Neurovascular tumor of the prostate is a very rare tu-
mor [16]. In the 61 years of material at our clinic it is the first 
case . The diagnosis is based on histopathological examina-
tion. Surgical treatment is the first step. More often adjuvant 
therapy is warranted (e. g radiotherapy). The prognosis is un-
certain [16]. Reoccurrence is often, especially in non-radical 
surgical procedures [16]. This case is presented because of 
the rarity of occurrence, difficult choice of treatment, and 
uncertain prognosis.
Our patient had a multiple cutaneous lesions (tubercle) 
on the shoulder and neck similar to a neurofibromatosis. Due 
to emergency related with necessity of resolving the case 
of prostate tumor, at the beginning we decided to perform 
only a surgical enucleation of the prostate tumor. After 
performed surgery the patient was discharged from the 
clinic after 3 weeks and did not return for the following dia-
gnostic (biopsy of tubercules) and treatment procedures. He 
died after 6 months at home due to cardiac insufficiency.
There was no history of malignancy in the family.
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